Rezolute, Inc. (RZLT) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.45
↓-23% vs avg
5yr avg: 1.88
30Y Low0.4·High10.0
ROE
↑
-52.6%
↓+18% vs avg
5yr avg: -64.2%
30Y Low-446%·High-39%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RZLT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Rezolute, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $295M | $339M | $221M | $101M | $63M | $109M | $27M | $18M | $25M | $47M | $25M |
| Enterprise Value | $203M | $246M | $153M | $88M | $-87278990 | $83M | $17M | $6M | $27M | $42M | $21M |
| P/E Ratio → | -3.15 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 1.45 | 2.09 | 1.83 | 0.87 | 0.42 | 4.19 | 3.63 | 10.04 | — | 5.47 | 2.82 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RZLT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
RZLT Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -52.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -52.6% | -52.6% | -57.7% | -39.0% | -46.8% | -124.9% | -446.0% | -1736.1% | -1307.7% | -234.4% | -167.6% |
| ROA | -48.3% | -48.3% | -53.4% | -37.5% | -42.1% | -78.0% | -175.2% | -412.3% | -454.8% | -188.3% | -134.8% |
| ROIC | -97.9% | -97.9% | -68.0% | -82.4% | — | — | — | — | -2293.3% | -344.7% | -256.4% |
| ROCE | -55.7% | -55.7% | -58.3% | -41.7% | -43.9% | -94.6% | -353.4% | -40579.3% | -1124.1% | -225.4% | -159.6% |
RZLT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $94M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.02 | 0.02 | 0.00 | 0.55 | 0.06 | 0.01 | — | 0.00 | 0.01 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.57 | -0.56 | -0.12 | -1.01 | -1.02 | -1.30 | -6.60 | — | -0.52 | -0.45 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -23.16 | -61.05 | — | -5.23 | -41.69 | -12742.35 | -2967.11 |
Net cash position: cash ($94M) exceeds total debt ($2M)
RZLT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Rezolute, Inc.'s current ratio of 14.37x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 20.18x to 14.37x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.37 | 14.37 | 13.39 | 20.18 | 61.78 | 21.34 | 3.26 | 1.45 | 0.32 | 2.78 | 2.60 |
| Quick Ratio | 14.37 | 14.37 | 13.39 | 20.18 | 61.78 | 21.34 | 3.26 | 1.45 | 0.32 | 2.78 | 2.60 |
| Cash Ratio | 14.09 | 14.09 | 13.21 | 19.60 | 61.09 | 20.86 | 3.09 | 1.38 | 0.26 | 2.53 | 2.35 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | 86.99 | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
RZLT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Rezolute, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $76M | $51M | $51M | $19M | $8M | $6M | $2M | $1M | $825934 | $495464 |
Peer Comparison
Compare RZLT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RZLTYou | $295M | -3.2 | — | — | — | — | -52.6% | -97.9% | — |
 XOMA | $490M | 28.3 | 37.5 | 170.6 | 94.3% | 21.8% | 38.2% | 7.4% | 9.2 |
 CGEM | $905M | -4.0 | — | — | — | — | -44.0% | -43.5% | — |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 VNDA | $378M | -1.7 | — | — | 94.0% | -70.0% | -50.9% | -32.2% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
 LLY | $921B | 42.5 | 30.6 | 102.7 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 NVO | $203B | 12.7 | 9.4 | 44.7 | 81.0% | 41.3% | 60.7% | 36.2% | 0.9 |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See RZLT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RZLT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RZLT vs XOMA
Side-by-side business, growth, and profitability comparison vs XOMA Royalty Corp..
Start ComparisonRZLT — Frequently Asked Questions
Quick answers to the most common questions about buying RZLT stock.
What is Rezolute, Inc.'s P/E ratio?
Rezolute, Inc.'s current P/E ratio is -3.2x. This places it at the 50th percentile of its historical range.
What is Rezolute, Inc.'s ROE?
Rezolute, Inc.'s return on equity (ROE) is -52.6%. The historical average is -146.2%.
Is RZLT stock overvalued?
Based on historical data, Rezolute, Inc. is trading at a P/E of -3.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.